 |
 |
|
|
Wellspring Biosciences�Enters Cancer R&D Agreement with Janssen Biotech
In February 2013,�Janssen Labs at San Diego tenant company�Wellspring Biosciences through its affiliate�Araxes Pharma, entered into an exclusive agreement with Janssen Biotech�to develop�first-in-class�therapeutics against�K-Ras for the treatment of cancer.��The work arose out of the research of UCSF Professor Kevan Shokat, one of the company�s founders and Chairman of the SAB. Shokat�s research, ultimately published in Nature, describes the discovery of small molecule allosteric inhibitors that bind to an oncogenic mutant, K-Ras G12C. �Under the agreement, Araxes Pharma�will advance its program through Phase I to clinical proof-of-concept.� Thereafter, Janssen Biotech will have sole responsibility for the continued development and worldwide commercialization of products arising under the agreement.�
|
|
|
|
 |
|
|
|
|
|
Assembly Receives Venture Investment from Johnson & Johnson Development Corporation
Janssen Labs @QB3 tenant Assembly Pharmaceuticals, a virology-focused biotech company, received an investment from Johnson & Johnson Development Corporation in collaboration with Johnson & Johnson Innovation. Assembly Pharmaceuticals� discovery platform is based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with Hepatitis B (HBV). CpAMs are being studied for their potential to provide curative rather than suppressive therapy for chronic Hepatitis B.
|
|
|
|
 |
|
|
|
|
|
Alector and Janssen Team Up for New Alzheimer's Disease Therapies
Antibody neuroscience company Alector, LLC, with operations at Janssen Labs @QB3, has established a research and development collaboration with Janssen Pharmaceuticals, Inc. Under the agreement, Janssen Pharmaceuticals will fund research in one of Alector�s targets through proof-of-concept disease models and will retain a time-limited option to negotiate a commercial agreement. The deal was done through the Johnson & Johnson Innovation Center in California.
|
|
|
|
 |
|
|
|
|
|
Triphase Inks Strategic Deal with Celgene
Cancer-focused accelerator, Triphase, with operations at Janssen Labs San Diego, signed an option agreement with Celgene Corporation. Under the strategic relationship, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept, plus a right of first negotiation on three more future oncology therapies. Financial terms were not disclosed.
|
|
|
|
 |
|
|
|
|
|
CURx Pharmaceuticals Enters Into Global License Agreement with Gilead
Janssen Labs at San Diego tenant CURx Pharmaceuticals entered into a global license agreement with Gilead Sciences, Inc. for development of a late-stage treatment for lung infection in cystic fibrosis patients. The company�s inhaled drug, Fosfomycin:Tobramycin, is designed to treat Pseudomonas aeruginosa lung infection in cystic fibrosis patients and is currently ready for Phase III clinical trials, following a reported successful completion of Phase II trials.
|
|
|
|
 |
|
|
|
|
|
Company Financing Round-Up
 |
RNA medicines company, Arcturus Therapeutics, with operations at Janssen Labs San Diego, raised $5 million in Series A funding for its lead candidate (LUNAR-101) for the treatment of rare diseases. |
|
|
Janssen Labs at @QB3 tenant, Bell Bio, raised an undisclosed amount in series A funding to increase their research and development efforts in producing synthetic organelles for life science research. |
|
|
|
|
|
|
|
|
|
